



## Omidria<sup>®</sup> (phenylephrine/ketorolac) – Expanded indication

- On December 12, 2017, [Omeros announced](#) the FDA approval of [Omidria \(phenylephrine/ketorolac\)](#), to include use in pediatric patients (ages birth through 17 years old) when added to an ocular irrigating solution used during cataract surgery or intraocular lens replacement and is indicated for maintaining pupil size by preventing intraoperative miosis and reducing postoperative ocular pain.
  - Previously, Omidria was only approved for use on adults.
  - Omidria was also granted an additional 6 months of market exclusivity.
- The safety and effectiveness of Omidria have been established in the pediatric population from neonates to adolescents (birth to younger than 17 years). In addition, use of Omidria in this population is supported by evidence from adequate and well-controlled studies of Omidria in adults with additional data from a single active-controlled safety study in pediatric patients up to 3 years old.
  - As in the adult studies, mydriasis was maintained in the Omidria-treated group in the pediatric safety study.
  - No overall differences in safety were observed between pediatric and adult patients.
- Omidria must be diluted prior to use for administration to a single patient undergoing cataract surgery or intraocular lens replacement. Omidria 4 mL should be diluted in 500 mL of ocular irrigating solution and used as needed for the surgical procedure.
  - The storage period for the diluted product is not more than 4 hours at room temperature or 24 hours under refrigerated conditions.
  - Omidria should not be used if the solution is cloudy or if it contains particulate matter.



OptumRx<sup>®</sup> specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum<sup>®</sup> company — a leading provider of integrated health services. Learn more at [optum.com](http://optum.com).

All Optum<sup>®</sup> trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews<sup>®</sup> is published by the OptumRx Clinical Services Department.

©2017 Optum, Inc. All rights reserved.